与疑似轻度认知障碍和阿尔茨海默病患者诊断评估相关的医师实践模式

Q1 Neuroscience International Journal of Alzheimer's Disease Pub Date : 2019-02-27 eCollection Date: 2019-01-01 DOI:10.1155/2019/4942562
Davneet Judge, Jenna Roberts, Rezaul Karim Khandker, Baishali Ambegaonkar, Christopher M Black
{"title":"与疑似轻度认知障碍和阿尔茨海默病患者诊断评估相关的医师实践模式","authors":"Davneet Judge,&nbsp;Jenna Roberts,&nbsp;Rezaul Karim Khandker,&nbsp;Baishali Ambegaonkar,&nbsp;Christopher M Black","doi":"10.1155/2019/4942562","DOIUrl":null,"url":null,"abstract":"<p><p>The diagnostic process for patients presenting with cognitive decline and suspected dementia is complex. Physicians face challenges distinguishing between normal aging, mild cognitive impairment, Alzheimer's disease, and other dementias. Although there is some evidence for improving attitudes towards the importance of prompt diagnosis, there is limited information describing how physicians approach this diagnostic challenge in practice. This was explored in the present study. Across-sectional survey of primary care and specialist physicians, in 5 European countries, Canada, and the United States, was conducted. Participants were asked about their use of cognitive screening tools and diagnostic technologies, as well as the rationales and barriers for use. In total, 1365 physicians participated in the survey, 63% of whom were specialists. Most physicians stated they use objective cognitive tools to aid the early detection of suspected mild cognitive impairment or Alzheimer's disease in patients. The Mini-Mental State Examination was the most common tool used for initial screening; respondents cited speed and ease of use but noted its lack of specificity. Cerebrospinal fluid biomarker and amyloid positron emission tomography tests, respectively, had been used by only 26% and 32% of physicians in the preceding 6 months, although patterns of use varied across countries. The most commonly cited reasons for not ordering such tests were invasiveness (for cerebrospinal fluid biomarker testing) and cost (for amyloid positron emission tomography imaging). Data reported by physicians reveal differences in the approaches to the diagnostics process in Alzheimer's. A higher proportion of primary care physicians in the United States are routinely incorporating cognitive assessment tools into annual visits, but this is due to country differences in clinical practice. The value of screening tools and regular use could be discussed further with physicians; however, lack of specificity associated with cognitive tools and the investment required from patients and the healthcare system are limiting factors.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2019 ","pages":"4942562"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/4942562","citationCount":"24","resultStr":"{\"title\":\"Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer's Disease.\",\"authors\":\"Davneet Judge,&nbsp;Jenna Roberts,&nbsp;Rezaul Karim Khandker,&nbsp;Baishali Ambegaonkar,&nbsp;Christopher M Black\",\"doi\":\"10.1155/2019/4942562\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The diagnostic process for patients presenting with cognitive decline and suspected dementia is complex. Physicians face challenges distinguishing between normal aging, mild cognitive impairment, Alzheimer's disease, and other dementias. Although there is some evidence for improving attitudes towards the importance of prompt diagnosis, there is limited information describing how physicians approach this diagnostic challenge in practice. This was explored in the present study. Across-sectional survey of primary care and specialist physicians, in 5 European countries, Canada, and the United States, was conducted. Participants were asked about their use of cognitive screening tools and diagnostic technologies, as well as the rationales and barriers for use. In total, 1365 physicians participated in the survey, 63% of whom were specialists. Most physicians stated they use objective cognitive tools to aid the early detection of suspected mild cognitive impairment or Alzheimer's disease in patients. The Mini-Mental State Examination was the most common tool used for initial screening; respondents cited speed and ease of use but noted its lack of specificity. Cerebrospinal fluid biomarker and amyloid positron emission tomography tests, respectively, had been used by only 26% and 32% of physicians in the preceding 6 months, although patterns of use varied across countries. The most commonly cited reasons for not ordering such tests were invasiveness (for cerebrospinal fluid biomarker testing) and cost (for amyloid positron emission tomography imaging). Data reported by physicians reveal differences in the approaches to the diagnostics process in Alzheimer's. A higher proportion of primary care physicians in the United States are routinely incorporating cognitive assessment tools into annual visits, but this is due to country differences in clinical practice. The value of screening tools and regular use could be discussed further with physicians; however, lack of specificity associated with cognitive tools and the investment required from patients and the healthcare system are limiting factors.</p>\",\"PeriodicalId\":13802,\"journal\":{\"name\":\"International Journal of Alzheimer's Disease\",\"volume\":\"2019 \",\"pages\":\"4942562\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2019/4942562\",\"citationCount\":\"24\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Alzheimer's Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2019/4942562\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Neuroscience\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Alzheimer's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/4942562","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Neuroscience","Score":null,"Total":0}
引用次数: 24

摘要

对表现为认知能力下降和疑似痴呆的患者的诊断过程是复杂的。医生面临着区分正常衰老、轻度认知障碍、阿尔茨海默病和其他痴呆症的挑战。虽然有一些证据表明,人们对及时诊断的重要性的态度有所改善,但描述医生在实践中如何处理这一诊断挑战的信息有限。本研究对此进行了探讨。对5个欧洲国家、加拿大和美国的初级保健和专科医生进行了横断面调查。参与者被问及他们对认知筛查工具和诊断技术的使用情况,以及使用的理由和障碍。共有1365名医生参与了调查,其中63%是专科医生。大多数医生表示,他们使用客观的认知工具来帮助早期发现疑似轻度认知障碍或阿尔茨海默病的患者。简易精神状态检查是最常用的初步筛查工具;受访者提到了速度和易用性,但指出其缺乏特异性。脑脊液生物标志物和淀粉样正电子发射断层扫描测试在过去6个月分别被26%和32%的医生使用,尽管使用模式因国家而异。不进行此类检查的最常见原因是侵入性(用于脑脊液生物标志物检测)和成本(用于淀粉样正电子发射断层扫描成像)。医生报告的数据揭示了阿尔茨海默病诊断过程方法的差异。在美国,较高比例的初级保健医生将认知评估工具纳入年度就诊,但这是由于各国临床实践的差异。筛查工具和定期使用的价值可以与医生进一步讨论;然而,缺乏与认知工具相关的特异性以及患者和医疗保健系统所需的投资是限制因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer's Disease.

The diagnostic process for patients presenting with cognitive decline and suspected dementia is complex. Physicians face challenges distinguishing between normal aging, mild cognitive impairment, Alzheimer's disease, and other dementias. Although there is some evidence for improving attitudes towards the importance of prompt diagnosis, there is limited information describing how physicians approach this diagnostic challenge in practice. This was explored in the present study. Across-sectional survey of primary care and specialist physicians, in 5 European countries, Canada, and the United States, was conducted. Participants were asked about their use of cognitive screening tools and diagnostic technologies, as well as the rationales and barriers for use. In total, 1365 physicians participated in the survey, 63% of whom were specialists. Most physicians stated they use objective cognitive tools to aid the early detection of suspected mild cognitive impairment or Alzheimer's disease in patients. The Mini-Mental State Examination was the most common tool used for initial screening; respondents cited speed and ease of use but noted its lack of specificity. Cerebrospinal fluid biomarker and amyloid positron emission tomography tests, respectively, had been used by only 26% and 32% of physicians in the preceding 6 months, although patterns of use varied across countries. The most commonly cited reasons for not ordering such tests were invasiveness (for cerebrospinal fluid biomarker testing) and cost (for amyloid positron emission tomography imaging). Data reported by physicians reveal differences in the approaches to the diagnostics process in Alzheimer's. A higher proportion of primary care physicians in the United States are routinely incorporating cognitive assessment tools into annual visits, but this is due to country differences in clinical practice. The value of screening tools and regular use could be discussed further with physicians; however, lack of specificity associated with cognitive tools and the investment required from patients and the healthcare system are limiting factors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Alzheimer's Disease
International Journal of Alzheimer's Disease Neuroscience-Behavioral Neuroscience
CiteScore
10.10
自引率
0.00%
发文量
3
审稿时长
11 weeks
期刊最新文献
Inflammatory Manifestations Associated With Gut Dysbiosis in Alzheimer's Disease. Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review. Novel Biomarkers for Alzheimer’s Disease: Plasma Neurofilament Light and Cerebrospinal Fluid In Silico Investigation of Novel Compounds as Inhibitors of Acetylcholinesterase Enzyme for the Treatment of Alzheimer's Diseases In Silico Investigation of Novel Compounds as Inhibitors of Acetylcholinesterase Enzyme for the Treatment of Alzheimer's Diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1